Chief Business Officer
CurrentA cancer company which has developed a novel first-in-class N-glycosylation inhibitor (small molecule) to a unique upstream cancer target ! Phase IB in solid tumours currently accruing patients in Europe Q3/Q4 2022 & RAISING A SERIES-B!